PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Prasugrel Dose Individualization: Balancing Ischemia and Bleeding by Population

A narrative review synthesizing prasugrel trial data with emphasis on reduced-dose strategies for Asian, elderly, and low-body-weight patients undergoing PCI.
prasugrelclopidogrelticagrelorP2Y12 inhibitorsdual antiplatelet therapyacute coronary syndromePCIbleeding riskdose individualizationAsian populationsnarrative review Cardiology / Anticoagulation

Background Information

Revisiting prasugrel: precision in antiplatelet therapy is key.

Prasugrel offers a potent antiplatelet option for ACS management but requires careful dosing to balance ischemic and bleeding risks. Evidence supports prasugrel use with dose optimization, indicating high efficacy and manageable bleeding risks in tailored patient populations. Prasugrel is particularly beneficial for patients undergoing complex PCI and specific Asian populations; however, patient selection and dose adjustment are crucial. Prasugrel should be tailored individually in ACS for optimal balance of efficacy and safety.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Kamisah Y, Che Hassan HH

Citation: Kamisah Y, Che Hassan HH Prasugrel: Reassessing Its Role in Contemporary Antiplatelet Therapy. Cardiovascular therapeutics. 2026;2026(1):e5538781. doi:10.1155/cdr/5538781

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →